Ubs Group Ag Cerevel Therapeutics Holdings, Inc. Put Options Transaction History

Ubs Group Ag

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 13, 2024	SELL	$38.96 - $42.75 $1.08 Million - $1.18 Million	-27,600 Reduced 48.94%	28,800 $1.18 Million
Q1 2024 May 13, 2024	SELL	$40.88 - $43.27 $1.86 Million - $1.97 Million	-45,600 Reduced 44.71%	56,400 $2.38 Million
Q4 2023 Feb 09, 2024	BUY	$20.27 - $42.44 $940,528 - $1.97 Million	46,400 Added 83.45%	102,000 $4.32 Million
Q1 2023 May 12, 2023	BUY	$22.82 - $35.32 $1.27 Million - $1.96 Million	55,600 New	55,600 $1.36 Million

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.